-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On April 29, BeiGene's new indication of belintoumumab for injection submitted by BeiGene was approved by the State Food and Drug Administration for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adults and children
Belintuumab is a CD3-CD19-targeting bispecific antibody developed based on Amgen's state-of-the-art Bispecific T Cell Engagement System (BiTE®)
Belintuumab was approved by the NMPA on December 4 last year through priority review for the treatment of adults with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL)
Belintoumumab was first approved by the FDA in December 2014